"There is a substantial number of risks associated with chemotherapy-induced nausea and vomiting (CINV)," said Susan Urba, MD, Medical Director, Symptom Management & Supportive Care Program, University of Michigan.
"There is a substantial number of risks associated with chemotherapy-induced nausea and vomiting (CINV)," said Susan Urba, MD, Medical Director, Symptom Management & Supportive Care Program, University of Michigan. The patient's quality-of-life is the main risk and concern of untreated CINV. Dr Urba also discusses the cost issues associated with uncontrolled CINV. Patient education is crucial in the prevention of unnecessary costs from extra office visits or hospitalization.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More